Shire's ADHD med Vyvanse holds off binge eating in trial for new indication

Shire ($SHPG) shares spiked to an all-time high after the company revealed new data showing its ADHD drug Vyvanse was effective at treating binge eating disorder. The company plans to ask the FDA next year to approve the new indication. Binge eating was newly recognized as an official disorder in the latest Diagnostic and Statistical Manual, which guides psychiatric treatment. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.